GenAssist Ltd Achieves FDA Clearance for Innovative Base Editing Treatment for Duchenne Muscular Dystrophy GenAssist Ltd proudly announces FDA approval for its groundbreaking base editing drug GEN6050X, aimed at treating Duchenne Muscular Dystrophy, marking a significant advancement in gene therapy.

GenAssist Ltd Achieves FDA Clearance for Innovative Base Editing Treatment for Duchenne Muscular Dystrophy #China #Suzhou #Duchenne_Muscular_Dystrophy #GenAssist_Ltd #GEN6050X